Altamira surges as nasal spray shows clinical superiority in study

Alpha AI Co

03/03/2023 16:22

** Shares of Bermuda-based biomedical co Altamira
Therapeutics Ltd  CYTO.O  rise 48.8% to $3.51 - top percentage
gainer across U.S. exchanges
    ** More than 18 mln shares have been traded, 1,200 times
more than its 10-day moving average
    ** Co says its U.S. FDA-approved anti-allergy nasal spray
Bentrio showed superior residence time to saline control in a
peer-reviewed clinical study on 8 healthy volunteers
    ** Long nasal residence time supports extended protective
effects against airborne allergens and other potentially harmful
particles - CYTO
    ** Bentrio remained in subjects' nasal passages for up to
210 minutes vs. saline nasal spray which remained for 60 minutes
   
    ** Study also showed Bentrio reached the oropharynx region,
an additional contactpoint for airborne viruses and allergens,
apart from nasal mucosa 
    **  Altamira is in discussions for Bentrio marketing and
distribution partnerships in North America, Europe and other key
markets
    ** CYTO down 80% in last 12 months

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))